A Phase 3 interventional study of Placebo and REGEND001 in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Regend Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Regend Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.
Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 168th largest by planned enrollment of the 286 interventional ones that give a count, is one of 34 that started in 2026, is one of 63 in phase 3, reaches primary completion later than 101 of the 124 other live ones, and was the 401st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 40–75
Tiantian Li · Sites in China
Ages 40–80
Nanfang Hospital, Southern Medical University · Sites in China
Ages 30–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
404 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 42 · Phase 3 66 · Phase 4 33
First in 2000; this study’s year is marked. 34 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 155 across the 286 interventional studies, 500 across the 118 observational. Of the 183 that completed or were terminated, 47 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
160 of 404 have an industry lead sponsor. The 10 most frequent:
Regend Therapeutics is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Regend Therapeutics has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
29 of the studies in Pulmonary Disease, Chronic Obstructive with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT07658339Phase 3Haisco Pharmaceutical Group Co., Ltd.A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | 2027-06-11 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07583849Phase 3Haisco Pharmaceutical Group Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD | 2027-09-30 |
Add all 29 to your calendar (.ics) → With an account.
Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Placebo Comparator arm will receive a single administration of placebo.
Biological: Placebo
Participants randomized to the experimental arm will receive a single administration of REGEND001.
Biological: REGEND001
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up.
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up.
Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
The change from baseline in measured DLCO is defined as the difference between the absolute measured DLCO value at baseline and that measured at the assessment time point after treatment.
Time frame: Week 52 after treatment
Change from baseline in COPD Assessment Test (CAT) score
The COPD Assessment Test (CAT) is an 8-item questionnaire used to assess the impact of COPD on health status. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD and worse health status. Change from baseline is calculated as the post-treatment CAT score minus the baseline CAT score.
Time frame: Week 12, 24 and 52 after treatment
Proportion of subjects with a ≥2-point improvement or worsening from baseline in CAT score
Minimal clinically important difference for CAT is recognized as 2 points.
Time frame: Week 12, 24 and 52 after treatment
Change from baseline in DLCO
DLCO is assessed by absolute measured value, hemoglobin (Hb)-corrected measured/predicted ratios and corresponding area under curve (AUC).
Time frame: Week 12, 24 and 52 after treatment
Proportion of subjects with a ≥11% relative improvement or worsening from baseline in absolute measured DLCO
Minimal clinically important difference (MCID) of DLCO is recognized as 11%.
Time frame: Week 12, 24 and 52 after treatment
Change from baseline in alveolar volume (VA)
VA is assessed by measured values, measured/predicted ratio and corresponding area under curve (AUC).
Time frame: Week 12, 24 and 52 after treatment
Change from baseline in forced expiratory volume in the first second (FEV1) post-bronchodilator
FEV1 is assessed by measured value, measured/predicted ratio and corresponding area under curve (AUC).
Time frame: Week 12, 24 and 52 after treatment
Change from baseline in 6-minute walk distance (6MWD)
6MWD is assessed by the measured value and corresponding area under curve
Time frame: Week 12, 24 and 52 after treatment
Proportion of subjects with a ≥30-meter change from baseline in 6MWD
Minimal clinically important difference (MCID) of 6MWD is recognized as 30 meters.
Time frame: Week 12, 24 and 52 after treatment
Change from baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) score
The St. George's Respiratory Questionnaire for COPD (SGRQ-C) is a validated disease-specific patient-reported outcome measure used to assess the impact of COPD on patients' health status and quality of life. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.
Time frame: Week 12, 24 and 52 after treatment
Proportion of subjects with a ≥4-point improvement or worsening from baseline in SGRQ-C score
Minimal clinically important difference for SGRQ is recognized as 4 points.
Time frame: Week 12, 24 and 52 after treatment
Annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics
The annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics, represents the adjusted frequency of acute exacerbations of COPD over the assessment period.
Time frame: Week 52 after treatment
Change from baseline in arterial blood gas parameters
The change from baseline in arterial blood gas parameters reflects changes in gas exchange function and respiratory status over the assessment period.
Time frame: Week 52 after treatment
Change from baseline in HRCT images
HRCT images are quantitatively analyzed using dedicated software to measure emphysema volume (mL) and functional lung volume (mL).
Time frame: Week 52 after treatment
Adverse Event
An adverse event (AE) is any untoward medical occurrence in a subject who has received a study intervention, regardless of whether or not it is considered related to the intervention.
Time frame: Hour 24, Week 12, 24 and 52 after treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 23 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: REGEND001
Pulmonary Disease, Chronic Obstructive →
Regend Therapeutics